Nucleic acid lateral flow immunoassay (NALFIA) is an innovative and powerful diagnostic technique that combines the specificity of nucleic acid amplification with the simplicity and rapidity of lateral flow immunoassays. This cutting-edge technology allows for the detection and quantification of specific nucleic acid targets in a variety of samples, providing a powerful tool in the field of infectious disease detection, food safety analysis, genotyping, and environmental contamination monitoring.
Lateral flow tests based on immunochromatographic principles are currently mainly used for the qualitative analysis of different types of analytes. A new promising application of lateral flow testing is the detection of genetic material. The method, called NALFIA, is a method that combines the principles of molecular biology detection with the principles of immunochemical visualization.
NALFIA is designed to test for the presence of amplified double-stranded nucleic acid sequences specific to the organism analyzed using primers with two different tags. Specifically, after DNA is isolated from the sample, a duplex PCR is performed using two primer sets, one of which is labeled with biotin and the other with either digoxigenin or fluorescein. The PCR solution and avidin-conjugated carbon particles are added directly to a nitrocellulose membrane, and two test lines are immobilized with dioxin- and fluorescein-specific antibodies. The appearance of black lines indicates the presence of a specific amplicon.
Fig. 1 Schematic picture of immunochromatographic test for nucleic acid detection. (Blazkova M, et al, 2009)
One key advantage of NALFIA is its sequence independence, allowing for the amplification of DNA/RNA targets before detection. This versatility enables the assay to be used in a wide range of applications, offering flexibility in detecting various nucleic acid sequences. And NALFIA is designed to be user-friendly and easy to operate. This accessibility makes it suitable for deployment in diverse settings, including resource-limited environments.
In addition, NALFIA is cost-effective compared to other nucleic acid detection methods. Unlike traditional techniques that involve the preparation of immunoassay reagents, such as antigens and antibodies, NALFIA primarily relies on the design of specific primers or hybridization sequences. This streamlined process contributes to reduced costs and faster turnaround times.
Furthermore, NALFIA distinguishes itself from traditional colloidal gold lateral flow immunoassays (LFIA) by its ability to detect infections even in the absence of antibodies (early infection) or when antibodies persist after a cure. By amplifying both DNA and RNA sequences before detection, NALFIA enhances the sensitivity and accuracy of pathogen detection, offering broader diagnostic capabilities.
In conclusion, by harnessing the potential of NALFIA, researchers, healthcare professionals, and food safety experts can enhance their ability to detect and monitor diseases, ensuring timely interventions and improving overall public health. Creative Diagnostics is committed to advancing NALFIA technology and providing high-quality products to meet the growing needs of the diagnostic industry. With our professional knowledge and commitment to innovation, we continue to support our customers and partners worldwide.
References
